Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemotherapy Plus Immune Checkpoint Inhibitor With or Without Bevacizumab After Disease Progression With First-line Alectinib of Advanced ALK-rearranged Non-small Cell Lung Cancer With 5'-ALK

Next Previous
X
Search
Trial Profile

Chemotherapy Plus Immune Checkpoint Inhibitor With or Without Bevacizumab After Disease Progression With First-line Alectinib of Advanced ALK-rearranged Non-small Cell Lung Cancer With 5'-ALK

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Immune checkpoint protein inhibitors (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CLASSIC5

    • Most Recent Events

    • 02 Apr 2024 Study design is changed from cohort, retrospective, observational to open, parallel, interventional. Treatment arms are added and upper age limit for inclusion criteria is added as 75 years.
    • 17 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top